Characterization of an in situ IFN-γ ELISA assay which is able to detect specific peptide responses from freshly isolated splenocytes induced by DNA minigene immunization

Journal of Immunological Methods

Volumn 237, Issue 1-2, 2000, Pages 105-117

  McKinney, Denise M ^a   Skvoretz, Rhonda ^a   Qin, Mingsheng ^a   Ishioka, Glenn ^a   Sette, Alessandro ^a  

^a Epimmune   (United States)

Author keywords

Cytotoxic T cells; DNA vaccines; ELISPOT; In situ ELISA

Indexed keywords

DNA VACCINE; GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; HLA SYSTEM; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL PROCEDURES; KINETICS; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; SPLEEN CELL; TARGET CELL;

AMINO ACID SEQUENCE; ANIMALS; ANTIGEN-PRESENTING CELLS; CHROMIUM RADIOISOTOPES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EVALUATION STUDIES; HLA-A2 ANTIGEN; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERON TYPE II; JURKAT CELLS; KINETICS; MICE; MICE, TRANSGENIC; PEPTIDES; SENSITIVITY AND SPECIFICITY; SPLEEN; VACCINES, DNA;

EID: 0034599886     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(00)00138-1     Document Type: Article

References (29)

1. Alexander J., Sidney J., Southwood S., Ruppert J., Oseroff C., Maewal A., Snoke K., Serra H., Kubo R., Sette A. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity. 1:1994;751.
2. Alexander J., del Guercio M.-F., Fikes J., Chesnut R., Chisari F., Chang K.-M., Appella E., Sette A. Recognition of a novel naturally processed, A2 restricted, HCV-NS4 epitope triggers IFN-gamma release in absence of detectable cytopathicity. Human Immunol. 59:1998;776.
3. Allen, T., Vogel, T., Fuller, D., Mothe, B., Steffen, S., Boyson, J., Shipley, T., Fuller, J., Hanke, T., Sette, A., Altman, J., Moss, B., McMichael, A., Watkins, D. Induction of AIDS virus-specific CTL activity in fresh, unstimulated PBL from Rhesus macaques vaccinated with a DNA prime/MVA boost regimen. J. Immunol., In revision.
4. Altman J., Moss P., Goulder P., Barouch D., McHeyzer-Williams M., Bell J., McMichael A., Davis M. Phenotypic analysis of antigen-specific T lymphocytes. Science. 275:1996;94.
5. 51Cr labeled allogenic target cells in vitro: inhibition by isoantibody and by drugs. Immunology. 14:1968;181.
6. Carter L., Swain S. Single cell analyses of cytokine production. Curr. Opin. Immunol. 9:1997;177.
7. Chisari F. Cytotoxic T-cell and viral hepatitis. J. Clin. Invest. 99:1997;1472.
8. Doherty P., Topham D., Tripp R. Establishment and persistence of virus-specific CD4+ and CD8+ T-cell memory. Immunol. Rev. 150:1996;23.
9. Dunbar P., Ogg G., Chen J., Rust N., van der Bruggen P., Cerundolo V. Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood. Current Biology. 8:1998;413.
10. Dutton R., Bradley L., Swain S. T-cell memory. Annu. Rev. Immunol. 16:1998;201.
11. Endresz V., Kari L., Berencsi K., Kari C., Gyulai Z., Jeney C., Pincus S., Rodeck U., Meric C., Plotkin S., Gonczol E. Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization. Vaccine. 17:1998;50.
12. Hanke T., Blanchard T., Schneider J., Hannan C., Becker M., Gilbert S., Hill A., Smith G., McMichael A. Enhancement of MHC class I-restricted peptide-specific T-cell induction by a DNA prime/MVA boost vaccination regime. Vaccine. 16:1998;439.
13. Hanke T., Schneider J., Gilbert S., Hill A., McMichael A. DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. Vaccine. 16:1998;426.
14. He X.-S., Rehermann B., Lopez-Labrador F.X., Boisvert J., Cheung R., Mumm J., Wedemeyer H., Berenguer M., Wright T., Davis M., Greenberg H. Quantitative analysis of hepatitis C virus-specific CD8+ T-cells in peripheral blood and liver using peptide-MHC tetramers. Proc. Natl. Acad. Sci. USA. 96:1999;5692.
15. Ishioka G., Fikes J., Hermanson G., Livingston B., Crimi C., Qin M., del Guercio M.-F., Oseroff C., Alexander J., Chesnut R., Sette A. Utilization of MCH class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. J. Immunol. 162:1999;3915.
16. Kagi D., Hengartner H. Different roles for cytotoxic T-cells in the control of infections with cytopathic versus noncytopathic viruses. Curr. Opin. Immunol. 8:1996;472.
17. Lefkovits I. From clones of cells to clones of genes. Folia Biol. (Praha). 40:1994;401.
18. McCutcheon M., Wehner N., Wensky A., Kushner M., Doan S., Hsaio L., Calabresi P., Ha T., Tran T., Tate K., Winkelhake J., Spack E. A sensitive ELISPOT assay to detect low-frequency human T lymphocytes. J. Immunol. Methods. 210:1997;149.
19. Murali-Krishna K., Altman J., Suresh M., Sourdive D., Zajac A., Miller J., Slansky J., Ahmed R. Counting antigen-specific CD8 T-cells: a re-evaluation of bystander activation during viral infection. Immunity. 8:1998;177.
20. Ogg G., Jin X., Bonhoeffer S., Dunbar R., Nowak M., Monard S., Segal J., Cao Y., Rowland-Jones S., Cerundolo V., Hurley A., Markowitz M., Ho D., Nixon D., McMichael A. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 179:1998;2103.
21. Ogg G., McMichael A. HLA-peptide tetrameric complexes. Curr. Opin. Immunol. 10:1998;393.
22. Pass H., Schwarz S., Wunderlich J., Rosenberg S. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J. Sci. Am. 4:1998;316.
23. Sedegah M., Jones T., Kaur M., Hedstrom R., Hobart P., Tine J., Hoffman S. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc. Natl. Acad. Sci. USA. 95:1998;7648-7653.
24. Stranford S., Skurnick J., Lourai D., Osmond D., Chang S., Sninsky J., Ferrari G., Weinhold K., Lindquist C., Levy J. Lack of infection in HIV-exposed individuals is associated with a strong CD8+ cell noncytotoxic anti-HIV response. Proc. Natl. Acad. Sci. USA. 96:1999;1030.
25. Taguchi T., McGhee J., Coffman R., Beagley K., Eldridge J., Takatsu K., Kiyono H. Detection of individual mouse splenic T-cells producing IFN-γ and IL-5 using the enzyme-linked immunospot (ELISPOT) assay. J. Immunol. Methods. 128:1990;65.
26. Tan L., Gudgeon N., Annels N., Hansasuta P., O'Callaghan C., Rowland-Jones S., McMichael A., Rickinson A., Callan M. A re-evaluation of the frequency of CD8+ T-cells specific for EBV in healthy virus carriers. J. Immunol. 162:1999;1827.
27. Vitiello A., Marchesini D., Furze J., Sherman L., Chesnut R. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med. 17:1991;1007.
28. Woodberry T., Gardner J., Mateo L., Eisen D., Medveczky J., Ramshaw I., Thomson S., Ffrench R., Elliott S., Firat H., Lemonnier F., Suhrbier A. Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8+ cytotoxic T-cell epitopes. J. Virol. 73:1999;5320.
29. Wunderlich J., Shearer G., Livingstone A. Assays for T-cell function: induction and measurement of cytotoxic T lymphocyte activity. Coligan J., Kruisbeek A., Margulies D., Shevach E., Strober W. Current Protocols in Immunology. Vol. 1:1997;3.11.18 John Wiley and Sons, USA.